
Phoreus Biotechnology, Inc.: Revolutionizing global One Health with proprietary peptide nanocarrier technology.
Phoreus Biotechnology, Inc. was founded with the mission to revolutionize global One Health through its proprietary peptide nanocarrier technology. The company focuses on precision drug delivery, particularly for the next generation of genetic vaccines and therapeutics. Phoreus offers two main technology platforms: Branched Amphipathic Peptide Capsules®️ (BAPC®️) and Corralling Amphipathic Peptide Colloids™️️ (CAPC™️️), which significantly enhance the efficacy of targeted, precision delivery systems.
Notable affiliated individuals and investors have not been disclosed publicly. However, Phoreus Biotechnology has achieved significant milestones in developing its proprietary platforms, positioning itself as a leader in the field of precision drug delivery. The impact of their technology promises to advance genetic technology and improve global health outcomes by providing more effective and targeted therapeutic solutions.

PhagePro
phageproinc.com

Aphios
aphios.com

PepVax
pepvax.co

Cytonus Therapeutics
cytonus.com

Extend Biosciences
extendbio.com

Phoresa

PhageTech
phagetech.com

Aera Therapeutics
aeratx.com

Atom Bioworks
atombioworks.com

Ampersand Biomedicines
ampersand.bio

Nano RED

Souvie Biodelivery

SmartPhage
pH Pharma
ph-pharma.com

Syntis Bio
syntis.bio
Companies similar to Phoreus Biotechnology include PhagePro, Aphios, PepVax and Cytonus Therapeutics.
Phoreus Biotechnology was founded in 2018.
Phoreus Biotechnology's headquarters is located in Olathe, KS, US.
Phoreus Biotechnology's most recent funding round was for $2.3M (USD) in May 2022.
As of May 11, 2022, Phoreus Biotechnology has raised a total of $3.1M (USD).
Phoreus Biotechnology has 5 employees as of Feb 5, 2024.